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ERIC R. BATES, MD. FACC 
Am Arbor, Mkltipor 
This review summarizes the multicenter trial results of 
reperfusion therapy for treatment of inferior myocardial 
infarction, Therapy with intracoronzy streptokinase or  
intravenous recombinant tissue plasminogen activator (rt- 
PA) produced higher patency rates than did intravenous 
streptokinase. Reocchtsion was more common when the 
right coronary artery was the infarct-related artery, irre- 
spective of treatment strategy. LeR ventricular ejection 
fraction was improved compared with that in control 
patients, especially when the time from symptom onset was 
brief or  when patency rates were high. Enzymatic infarct 
size was redmod in treated patients. A trend toward 
mortality reduction in treated patients was found in four 
studies and was statistically significant in the Second Inter- 
national Study of Infarct Survival (ISIS-2) trial. 
Precordlal ST segment depression in inferior myocar- 
The use of thrombolytic therapy in patients with inferior 
myocardial infarction has been a controversial subject. 
Whereas it is generally acknowledged that patients with 
anterior myocardial infarction benefit from thrombolytic 
therapy, the utility of treating patients with inferior infarc- 
tion, in whom the clinical course tends io be relatively 
benign. has been more difficult for many clinicians to accept. 
Consequently, some investigators (I) have recommended 
that thrombolytic therapy be limited to patients with anterior 
myocardial infarction. 
When examined in aggregate, however, a substantial 
amount of data from conlrolled randomized multicenter 
trials supports the use of thrombolytic therapy in inferior 
infarction. The purpose of this report is to summarize the 
results of those trials. When these data are analyzed in the 
context of time to treatment, coronary patency and reocclu- 
sion rates and ischemic burden, strong support for the 
application of thrombolytic therapy in most patients with 
inferior infarction becomes apparent. 
From the Dwsion of Cnrdrology. Department of Internal Medicine, 
Unwer~~ly of Mlchq,an. Ann Arbor. Micblgan. 
-for Eric R .  Bates. MD,  Division ofCardmlogy. Univer- 
sdy Hospital. 1500 East Medical Cenler Drive. 3910 ‘Taubman. Ann Arbor. 
Michigan 481139-0366. 
Multicenter Tiwumbolytic Trial Designs 
Eleven multicenter trials have published data concerning 
inferior myocardial infarction before March 1988. The trials 
can be grouped into intracoronary streptokinase trials, intra- 
venous streptokinase trials and intravenous recombinant 
tissue plasminogen activator (r&PA) trials (Table I). 
Intracoronary streptokinnse trials. The Western Wash- 
ington lntracoronary Streptokinase (WWlCS) trial (2-7) 
carolled 134 patients with inferior infarction among a total of 
250 study patients in 14 hospitals from July 1981 to February 
1983. Patients admitted within 12 h of symptom onset 
underwent cardiac catheterization, and those randomized to 
intracoronary streptokinase therapy received an average of 
286,000 U infused over 72 min. Mean time to randomization 
was 4.6 h; only 22% of patients were randomized in <3 h. 
Mechanical revascularization (angioplasty or bypass graft 
surgery) was accomplished in 10% of patients within 30 days 
and in 26% of patients by I year. All patients were treated 
with heparin, followed by warfarin. 
The Nerherktnds Inferrtniversiry friul (8-18) entered 287 
patients with inferior myocardial infarction among a total of 
533 study patients in five hospitals from June 1981 to March 
1985. Patients with symptoms ~4 h in duration were eligible 
to undergo cardiac catheterization and an intracoronary 
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streptokinase infusion of 250,000 U over I h. Control pa- 
tients did not undergo emergency cardiac catheterization. 
Elective cardiac catheterization was performed in 76% of the 
total patient group just before hospital discharge. Forty-four 
percent of the treatment group were pretreated with 500.000 
IJ of intravenous streptokinase and 17% underwent emer- 
gency angioplasty. Mean time to treatment was 3.3 h. 
Mechanical revascularization was performed in 15% of the 
control patients and 3% of the treatment patients by I year. 
Patients were also treated with aspirin, heparin and an oral 
anticoagulant agent. 
Intravenous streptokioaw trials. The Gruppo Italian0 per 
lo Studio della Streptochinasi nell’lnfarto Miocardico 
(GISSI) trial (N-22) enrolled 4,013 patients with inferior 
myocardial infarction among a total of Il.806 study patients 
in 176 coronary care units from February 1984 to June ,485. 
Patients admitted within I2 h of symptom onset and random- 
ized to treatment received I.5 million U of intravenous 
streptokinase over 60 min. Half of the patients were treated 
within 3 h. Cardiac catheterization was not performed. Ten 
percent of the patients were older than 75 years and 50% 
were older than 65 years. Only 20% received heparin and 
14% received aspirin. Fewer than 4% of patients underwent 
mechanical revascularization, making the control group a 
cohort of medically treated patients followed up for I year 
after acute myocardial infarction. 
The Intravenotrs Streptokinase in Actrte Myocardial Iv- 
firction (HAM) trial (23-25)  entered 877 patients with 
inferior infarction among a total of I.741 study patients in 38 
hospuals from March 1982 to March 1985. Patients admitted 
within 6 h of symptom onset and randomized to streptoki- 
nase received I.5 million U over I h. Half of the patients 
Yere treated within 3 h. Emergency cardiac catheterization 
was not performed, but 53% underwent cardiac catheteriza- 
tion 4 weeks later. Patients were treated with aspirin, 
heparin and an oral anticoagulant agent. Mechanical revas- 
cularization was undertaken in I I% of patients by 7 months. 
The NW Zealand trial (26) enrolled 91 patients with 
inferior infarction among a total of I55 study patients with a 
first myocardial infarction in four hospitals from August 1984 
to August 1986. Patients admitted within 4 h and randomized 
to intravenous strep:okinase received I.5 million U over 30 
min. Mean time to treatment was 3 h. Cardiac catheteriza- 
tion was performed 3 weeks later. Patients were also treated 
with aspirin, dipyridamole and heparin. 
The Western Washington Intravenous Streptokinase in 
Acrrte Myocardial Ittfarction trial (27) enrolled 234 patients 
with inferior infarction among a total of 368 study patients in 
27 hospitals from September 1983 to July 1986. Patients 
randomized within 6 h to streptokinase received 1.5 million 
U over I h. Mean time to treatment was 3.5 h. Streptokinase- 
treated patients were also treated with heparin and warfarin. 
Mechamcal revascularization was performed in 11% of pa- 
tients before hospital discharge. 
Intravenous tissue plasminogen activator trials. The 
Thrombolysis in Myocardial Infarction (TIMI) phase I trial 
(28-30) entered I I9 patients with inferior infarction among a 
total of 232 study patients with occluded infarct-related 
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arteries in 13 hospitals from August 1984 to February 1985. 
Patients were treated within 7 h and received either I.5 
million U of imravenous streptokinase over I h or 80 mg of 
double chain rt-PA over 3 h. Mean time to treatment was 4.8 
h. Patients were also treated with aspirin, dipyridamole and 
heparin. Mechanical revascularization was performed in 
24% of patients before hospital discharge. 
The Thrombolysis and Angioplasty in Myocardial Infarc- 
rioa (TAM/) trial (31,32) enrolled 223 patients with inferior 
infarction among a total of 386 study patients in four hospi- 
iais fiOlX Deccmbc: .,.,> lo*< !o Cc!ober !9Rh All patients 
received 150 mg of single chain r&PA intravenously within 6 
h of symptom onset. Mean time to treatment was 2.9 h. 
Suitable patients were randomized to immediate or delayed 
angioplasty. Patients were also treated with aspirin, dipyri- 
damole and heparin. Mechanical revascularization was per- 
formed in 67% of patients before hospital discharge. 
after acute myocardial infarction. The Hopkins trial (33) 
randomized 80 patients with inferior myocardial infarction 
and measured ejection fraction 10 days later. The Throm- 
bolysis in Acute Coronary Occlusion (TICO) trial (34) ran- 
Three smaller placebo-controlled trials evaluated the ef- 
fect of earlv treatment with r&PA on left ventricular function 
Table 2. Acute Patency Rates in Inferior and Anterior 
Myocardial infarction 
Time to 
Patency (%) 
NO. Rx(h) IMI AMI -  
lntracoronary SK 
WWICS (2)  
Nerherlands (13)  
tntravenous SK 
ISAM (25)  
TIMI-I (28)  
lnlravenous r&PA 
TIMI-I (28)  
TAMI-I (37)  
134 4.6 -68 -68 
287 3.3 88 83 
877 3 -34 -48 
57 4.8 35 28 
62 4.8 53 7: 
233 2.9 68 (91)  77 (%) 
AM1 = anterior myocardial infarction: other abbreviations as in Table I. 
Figures in parentheses represent palency rates after addition of immediate 
angioplasty to thrombolytic therapy. 
infarction. This was believed to imply a higher reperfusion 
rate in patients with anterior infarction. With use of angio- 
graphic criteria, the TIMI-I trial (28) reported a 35% reper- 
fusion rate of occluded arteries in inferior infarction with 
with inferior infarction versus 48% of those with anterior 
domized 69 patients with inferior myocardial infarction and 
measured ejection fraction 21 days later. The National Heart 
Foundation of Australia Coronary Thrombolysis Group (35) 
randomized 84 patients with inferior myocardial infarction 
and measured ejection fraction I week later in 61 patients. 
Multicenter Trial Results in Inferior 
Myocardial Infarction 
The factors that need to be considered when determining 
the efficacy of a coronary repetfusion strategy include time 
to treatment, coronary patency, reocclusion, left ventricular 
function, infarct size and mortality rate. 
Coronary Patency (Table 2). Patency rates after throm- 
bolytic therapy are presented in Table 2. lntracoronary 
streptokinase appears to be equally effective in recanalizing 
occluded coronary arteries independent of infarct location. 
Although the WWICS trial has not reported its patency rate 
by infarct location. the overall 68% patency rate (2) is almost 
identical to the 72% patency rates for both anterior infarction 
and inferior infarction recorded in the lntracoronary Strep 
tokinase Registry of the Society for Cardiac Angiography 
(36). for which time to treatment was similar. Earlier treat- 
ment with intracoronary streptokinase in the Netherlands 
trial (13) was associated with a patency rate of 88% for 
inferior infarction and 83% for anterior infarction. 
Patency rates, however, decrease with intravenous 
thrombolytic therapy, particalarly with streptokinase, and 
seem to be lower in inferior than in anterior myocardial 
infarction. In the ISAM study (25). creatine kinase (CK) MB 
isoenzyme levels peaked in less than 9 h in 34% of patients 
streptokinase. which improved to 53% with rt-PA. Corre- 
sponding results in anterior infarction were 28 and 71%. 
respectively. In the TAMI-I trial (31), in which time to 
treatment was earlier and a high dose of single chain rt-PA 
was used, the patency rate in inferior infarction was 68% 
after thrombolytic therapy and 91% after additional therapy 
with immediate angioplasty compared with the results in 
anterior infarction in which patency raies were 77 and %%, 
respectively (37). Thus, it appears that early intracoronary 
streptokinase and intravenous r&PA are significantly more 
effective than intravenous streptokinase in establishing re- 
perfusion in inferior myocardial infarction and that angio- 
plasty can further increase reperfusion rates. The lower 
patency rates in inferior infarction with intravenous therapy 
may be due to larger thrombus volume in the right coronary 
artery (30). Decreased branching (30). increased recruitment 
of collateral circulation (6), increased tortuosity, lower re- 
sistance in the right ventricular perfusion bed and increased 
vagal tone are some of the explanations for lower blood flow 
velocity in the infarct-related artery and the potential for 
increased stasis and thrombosis. 
Reocciusion. Coronary reocclusion after successful 
thrombolysis frequently compromises the gains achieved by 
reperfusion in terms of myocardial salvage and potential 
effect on infarct healing. A significant limiting factor in the 
long-term outcome of patients after inferior myocardial 
infarction is that reinfarction or reocclusion is more common 
than in anterior myocardial infarction irrespective of the 
reperfusion strategy. The Netherlands trial (15) showed a 
1% I year reinfarction rate after inferior infarction com- 
pared with an 8% rate after anterior infarction (p = 0.008). 
Table 3. Left Ventricular EJCC~W Fr;~ctwn m Infcrtor 
Myocmlial Infarction 
LVEF I’;1 
Time 10 rre.,led Control 
Trlrl n  Rx Ihl PI\ PI\ p V.due 
Strcptokmw 
WWICS IX wkll3l IIX 46 52 49 I, II 
WWIVS II0 day\) 127)  I?1 15 ii 5, 0 w 
Netheiland\ 00 day\) IlO) IX4 1 3 57 49 0 IWU,, 
NZ (3 wkl 1261 91 1 ,I M, 55 I, II5 
CPA 
Hopkins II0 day51 11% HO 1? 59 $4 I, OS 
TIC0 I3 wkll34) SY i j g, C’> !! !!!7 
Aurrralia II wk) ,351 61 13 h! 57 0 IO 
LVEF = Ien ventricular e~emcn fracmn. &her dbbrwwm\ ,I* m 
Table I. 
Reocclusion of the right coronary artery \eems to be the 
major problem. The ISAM (24)  trial reported a 20% reocclu- 
sion rate in the right coronary artery within 4 week\ of 
streptokinase therapy versus % in the left anterior descend- 
ing coronary artery. The TAMI-I (37)  trial found a 21% 
reocclusion rate in the right coronary artery I week after 
r&PA compared with 12% in the left anterior descendmg 
artery and 5% in the left circumflex artery (p = 0.01). 
Similarly, in the TAMI- trial with 1 h infusions of r&PA and 
urokinase, the I week reocclusion rate was 67, i:: :bc left 
anterior descending and 18% in the right coronary artery 
(unpublished data). Futurb treatment strategies ih?! de 
crease reocclusion rates would particularly improve the 
results of acute intervention in inferior myocardial infarc- 
tion. 
Left ventricular function (Table 3). Preservation of left 
ventricular function is largely dependent on the time to 
treatment and coronary patency rate. Data on left ventricu- 
lar ejection fraction in inferior infarction are available from 
seven trials (3,10,26,27.33-35.) (Table 3). All show preser- 
vation of left ventricular ejection fraction in treated patients 
compared with control patients. The Western Washington 
trials did not show a statistically significant difference. but 
the average time to treatment in the intracoronary trial was 
much longer than in the other trials. whereas the intravenous 
trial reported data from only 52% of the patients. The best 
results were seen when the time from symptom onset lo 
treatment was brief (TIC0 trial) or  when patency rates were 
high (Netherlands trial). The ISAM trial (23)  also showed a 
statistically significant improvement in patients treated 
within 3 h of symptom onset, but did not publish the 
numerical ejection fractions. These results are especially 
impressive given that improvement in ejection fraction is 
more difficult to demonstra!e when the baseline ejection 
fraction is >50%, as is often the case in inferior infarction 
(38). 
De.,lh\ Ipi, 
Infarct size. Enzymatically determined mtarct size was 
mca\ured in two studies. The Netherlands trie! !:4). with 
high reperfuslon rates, demonstrated a 31% reduction in 
Infarct \ire (p = O.OiI7) in treated patients. The ISAM trial 
(25). with lower reperfusion rates. demonstrated a 14% 
reduction m Infarct size (p = 0.03) m treated patients. 
Mortality (Tables 4 and 5). The mortality rates associated 
wi:b inferior myocardial infarction are lower than those qeen 
with anterior infarction. For a proportionately similar bene- 
ficlal effect of thrombolytic therapy on mortality rate to be 
demonstrated. larger patient sample sizes will be required. A 
\tati\tically Imignificant trend in favor of mortality reduction 
in treated patients was found in four placebo-controlled 
studies (2,4.13.15,19,21.24.25). but not in the Western Wash- 
ington mtravenuus trial (271 (Tables 4 and 5). The inadequate 
study size limited the statistical power of the two intracoro- 
nary studies. whereas the intravenous streptokinase trials 
were limited by the low patency rates associated with that 
therapy. Moreover, a comparison of the mortality rates in 
the control groups suggests that the patients enrolled in the 
Western Washington trials had a much lower mortality risk 
than was observed in the other trials. Other limitations in the 
GISSI trial (19)  include older patient age, symptom duration 
up :o I2 h and absence of anticoagulant therapy after 
thrombolytic therapy. The Netherlands trial (l3), in which 
time to treatment was relatively brief and patency rate? were 
highest. demonstrated the best short-term survival benefit ;,I 
treated patients. Further support for survival benefit in 
patients with inferior myocardial infarction treated with 
Table 5. Late Mortality in Inferior Myocardia! Infarction 
-  ~--.-- 
Deaths I%) 
No. of Treated Control 
Tml Pat1entr Group Group 
WWICSII yrlI1) 134 1.4 6.3 
Netherlandr II yr) 051 287 8.6 II 5  
GISSI II yr) 121)  4m3 II.6 12.6 
ISAM I31 mu, I29 877 12.3 16.3 
WWIVS I? yrl 127)  234 II.0 7.0 
AbbrevWm\ as I” Table I 
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Streptokinase trial. 
thromho$ic therapy was found in the large ISIS-2 trial (39). 
in which there was a siatistically significant reduciion in 
morlality in both anterior and inferior infarction after intra- 
venous streptokinase. 
Myocardial Infarct Size 
The site of infarct artery occlusion and the extent of the 
arterial distribution are important determinants of infarct 
size. 
Site of infarct artery occlusion (Table 6). Data ?re avail- 
Figure 1. Right anterior oblique projections of a nondominant 
circumflex coronary artery (upper panel) and a codominanl circum- 
Rex coronary artery with a large posterolaleral branch (lower panel). 
able on the site of infarct artery occlusion from the WWlCS 
trial (6) and the TAMI-I trial (Table 6). These trials and 
others, using ST segment elevation as entry criteria, have 
consistently noted that the infarct-related artery is the left 
anterior descending coronary artery in 40 to 45% of patients, 
the right coronary artery in 40 to 45% of patients and the left 
circumflex coronary artery in IO to IS% of patients. When 
the left anterior descending artery is the infarct-related 
artery, the site of occlusion is proximal to the first diagonal 
branch in approximately 70% of patients and before the 
second diagonal branch in another 25%; the distal artery and 
diagonal branches are involved in <5%. When the right 
coronary artery is the infarct-related artery, the site of 
occlusion is almost always proximal to the entire left ven- 
tricular perfusion bed, occurring before the first right ven- 
tricular branch in 55% of patients and in the middle and distal 
artery in approximately 43% of patients. In the circumflex 
artery, 20% of the occlusions are in an obtuse marginal 
branch and Ro% are in the atrioventricular (AV) circumflex 
branch. Thus, it appears that the electrocardiographic (ECG) 
criterion of ST segment elevation is very effective in exclud- 
ing patients fer thrombo!ytic therapy with distal left anterior 
descending or posterior descending artery occlusion and 
with small diagonal or marginal branch occlusion. 
Anatomic variation in coronary artery distribution. The 
left anterior descending coronary artery consistently gives 
off perforator branches to the intraventricular septum and 
diagonal branches to the anterolateral wall. The distal artery 
usually reaches the apex of the ventricle, though it may stop 
short or wrap around the apex to the diaphragmatic segment. 
In contrast, the circum&ex and right coronary arteries have 
more variable anatomy. The posterior descending coronary 
artery is part of the right coronary circulation in 90% of 
patients and the left circumflex artery in 10% of patients. 
Perhaps more important for the purposes of this discussion is 
the variation in distribution of the posterolateral branches, 
which can be small or large, number from one to three and 
originate from either the circumflex or the right coronary 
artery (Fig. I and 2). 
lschemic burden. When both the site of occlusion of the 
infarct-related artery and anatomic variation in coronary 
artery distribution are considered, it becomes apparent that 
Fiire 2. Left anterior oblique projections of a codominant right 
coronary artery (upper panel) and a dominant right coronary artery 
with large posterolateral branches (lower panel). 
anterior infarction is a fairly homogeneous entity, whereas 
inferior infarction is a heterogeneous entity. Anterior infarc- 
tion almost always involves the anterolateral ventricular 
segment and part or all of the left ventricular apex. The high 
frequency of proximal arterial occlusion usually involves the 
anteroseptal segment in the infarct as well. In contrast, 
inferior infarction can be limited to only the posterobasal or 
diaphragmatic or posterolateral segments. depending on the 
size of the infarct-related artery, or it can involve two or 
three of the segments. Additionally, the apical segment can 
be involved, and if the occlusion is in the proximal right 
coronary artery, right ventricular infarction can occur con- 
comitantly. A major limitation in all of the randomized trials 
is that the variable ischemic burden in inferior myocardial 
infarction has not been considered in the analyses of left 
ventricular function or mortality. 
ECG infarct size. Several studies (40-43) in the last 
decade have documented that the presence of precordial ST 
segment depression in inferior wall myocardial infarction is 
associated with CK enzyme release, acute left ventricular 
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Figure 3. Treatment algorithm for patients with inferior 
myocardial infarction who present within 6 h of symp 
tom onset. Cath = cardiac catheterization; HTN = 
hypertension: IV = intravenous; FTCA = percutaneous 
transluminal coronary angioplasty: rt-PA = recombi- 
nant tissue plasminogen activator: Rx = treatment: Sx 
= symp!om onset. 
perhaps because of the larger thrombus volume in the right 
coronary arlery (30). The superior efficacy of intravenous 
r&PA versus s!reptokinase in recanalizing older and perhaps 
larger thrornbi is of particular importance in inferior infarc- 
tion, in which infarct size tends to be smaller and right 
coronary artery reocclusion rates remain about 20% regard-  
less of treatment strategy. 
Figrrrc 3 presmts a ~rcutn~ct~t crlgoriflrrn for acute inferior 
infarction that takes into consideration the bleeding risk 
a.sociated with reperfusion therapy and the potential bene- 
fits of arierial patency and preservation of ventricular func- 
tion. The inability of previous trials to demonstrate a sur- 
vival benefit in inferior infarction can be explained by 
limitations in study design. It should be expected that when 
time to treatment is rapid, recanrlization rates are high, left 
ventricular function is preserved and adequate sample sizes 
are tested, then mortality rates can be decreased by reper-  
fusion therapy independent of infarct location. 
-  
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